DNLI — Denali Therapeutics Inc.

—
Nasdaq · Health Care · Biotechnology · CIK 1714899 ·
Last close
$18.00
Market Cap
$2.89B
52W High
$27.30
52W Low
$15.34
ADV30
1,636,320
Next earnings
2026-11-03

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 17,778,000 17,586,000 -126,751,000 70,126,000 1,256,035,000 102,870,000 329,648,000
Jun 2026 3,604,000 3,511,000 -130,541,000 -127,553,000 1,157,955,000 201,530,000 322,777,000
Mar 2026 0 — -137,357,000 -128,447,000 1,266,023,000 387,626,000 339,925,000
Dec 2025 0 — -137,365,000 -128,549,000 1,144,854,000 205,326,000 131,093,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-444,187,000
Investing CF
$27,341,000
Financing CF
$428,753,000
CapEx
$-41,805,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.73
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$-2,237,398,000
Inventory
$26,275,000
Receivables
$18,882,000
ST Investments
$413,326,000
EBIT TTM
$-532,014,000
Pretax Income TTM
$-314,321,000
Interest Exp TTM
—
Analysts
16

Yahoo Snapshot (yfinance, live)

Total Revenue
$21,382,000
EBITDA
$-513,996,000
Free Cash Flow
$-301,324,256
Enterprise Value
$2,736,076,288
Total Cash
$516,196,000
Total Debt
$35,241,000
Shares Out
160,290,546
Trailing EPS
$-1.72
Book Value
$5.78
ROE
-33.9%
ROA
-28.7%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -555,342,000 -512,540,000 1,144,854,000 131,093,000 1,013,761,000 -412,600,000
Dec 2024 0 -501,878,000 -422,773,000 1,374,180,000 144,496,000 1,229,684,000 -347,694,000
Dec 2023 330,531,000 -196,699,000 -145,224,000 1,153,917,000 122,963,000 1,030,954,000 -357,991,000
Dec 2022 108,463,000 -340,744,000 -325,991,000 1,460,242,000 417,812,000 1,042,430,000 -244,716,000

TTM Snapshot

Revenues TTM
$3,604,000
NetIncome TTM
$-511,451,000
OpCashFlow TTM
—
Assets (Latest)
$1,157,955,000
Forward EPS
$-2.27

Max Pain — expiry 2026-12-18

max pain strike: $20.00 · spot: $18.40 · call oi: 2,397 · put oi: 5,300
Expected Move to 2026-12-18: ±$2.92 (15.90%) — implied range $15.47 – $21.32 · ATM straddle on $17.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
VCEL Vericel Corp $2.95B $57.88 —
ADMA ADMA BIOLOGICS, INC. $3.02B $13.63 —
IOVA IOVANCE BIOTHERAPEUTICS, INC. $3.48B $7.53 —
RLAY Relay Therapeutics, Inc. $3.64B $16.47 —
TARS Tarsus Pharmaceuticals, Inc. $3.86B $78.20 —

News headlines (Yahoo Finance, 1h cache)

Denali Therapeutics Targets All Eligible Hunter Disease Patients as Pipeline Milestones Near
2026-11-13 13:14 · Yahoo
Guggenheim reaffirms top pick in Biotech after Q3 results
2026-11-09 20:26 · Yahoo
Should Earnings Beat Require Action From Denali Therapeutics Stock Investors?
2026-11-06 15:17 · Yahoo
Is Denali Therapeutics (DNLI) Already Priced Right For Its Cash Flow?
2026-11-06 03:22 · Yahoo
Denali Therapeutics (DNLI) Earnings Beat Puts Valuation Back In Focus
2026-11-06 01:19 · Yahoo
DNLI Up 7.8% Post Q3 Earnings: Should You Buy, Sell or Hold the Stock?
2026-11-05 18:01 · Yahoo
Denali Therapeutics Inc (DNLI) Q3 2026 Earnings Call Highlights: AVLAYAH Revenue Soars Nearly ...
2026-11-04 17:05 · Yahoo
Denali (DNLI) Q3 2026 Earnings Call Transcript
2026-11-04 15:29 · Yahoo
Denali Therapeutics Inc. Q3 2026 Earnings Call Summary
2026-11-04 13:30 · Yahoo
Denali Therapeutics Q3 Earnings Call Highlights
2026-11-04 00:14 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.